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Background
The mucosal surface is the major route for HIV-1 trans-
mission, yet a safe and effective AIDS vaccine through
direct mucosal immunization remains elusive.
Methods
Here, we report a novel vaccination regimen consisting of
a mucosal prime with replication-competent vaccinia
Tiantan rMVTTSIVgpe and an intramuscular boost with
non-replicating rAd5SIVgpe expressing SIV Gag, Pol and
Env. Twenty Chinese rhesus macaques were used to evalu-
ate its safety, immunogenicity and protective potential.
Results
Compared with three control groups, the rMVTTSIVgpe-
rAd5SIVgpe regimen elicited robust cellular immune
responses with enhanced magnitude, sustainability and
polyfunctionality, and higher titers of neutralizing antibo-
dies against SIVmac1A11. Moreover, one rMVTTSIVgpe-
rAd5SIVgpe vaccinated animal was fully protected, while
the rest demonstrated 1.74-log and 1.2-log reductions in
peak and set-point viral loads upon intrarectal challenge
with a high dose (5x105 TCID50/animal) of a pathogenic
and neutralization-resistant SIVmac239. Importantly, the
rMVTTSIVgpe-rAd5SIVgpe vaccinated animals remained
healthy up to 850 days post-challenge, while the majority
(~75%) of controls progressed to simian AIDS. The pro-
tective effect was found to correlate with SIV-specific
CD8+ T cell ELIspot responses against Gag and Pol, but
not Env.
Conclusion
Our findings indicate that vaccine strategy engaging the
mucosal surface from the beginning of vaccination may
provide protective immunity against HIV-1 infection in
humans.
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